FIELD: pharmaceuticals.
SUBSTANCE: invention relates to the field of pharmaceuticals, namely to application of a biologically active supplement containing oxyethylammonium methylphenoxyacetate, beta-carotene, alpha-tocopherol, garlic and lactose as preparation increasing the concentration of ferritin in blood serum. The biologically active supplement is used at a dosage of 400 mg/day for a person 15 to 30 minutes before meals during the first 3 weeks, and then in a similar repeated course in the 4th month of treatment by basic medicinal products.
EFFECT: invention provides increased concentration of ferritin in human blood serum.
1 cl, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT INCREASING FERRITIN CONCENTRATION IN HUMAN BLOOD SERUM | 2022 |
|
RU2794847C1 |
| MEDICATION MODULATING CONCENTRATION OF FERRITIN IN BLOOD SERUM | 2012 |
|
RU2486895C1 |
| A MEANS OF INCREASING THE LEVEL OF LACTOFERRIN IN THE BODY | 2020 |
|
RU2744757C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF ANAEMIA OF CHRONIC DISEASES AND IRON DEFICIENCY ANAEMIA IN PATIENTS WITH INFLAMMATORY JOINT DISEASES | 2024 |
|
RU2825523C1 |
| METHOD OF DIAGNOSING DESTRUCTIVE FORMS OF ACUTE CHOLECYSTITES | 2009 |
|
RU2407017C1 |
| MEDIATION INCREASING LEVEL OF LACTOFERRIN IN ORGANISM | 2012 |
|
RU2486894C1 |
| METHOD FOR RAPID DIAGNOSIS OF THE SEVERITY OF PNEUMONIA IN COVID-19 | 2022 |
|
RU2789426C1 |
| METHOD FOR PREDICTING THE SEVERITY OF PNEUMONIA IN COVID-19 | 2022 |
|
RU2795093C1 |
| METHOD FOR PREDICTING OUTCOMES OF PNEUMONIA IN COVID-19 | 2022 |
|
RU2795095C1 |
| METHOD FOR TREATING ANEMIA DURING PREGNANCY | 2006 |
|
RU2319489C2 |
